Maze Therapeutics disclosed positive mid-stage topline results for MZE829, an oral APOL1 inhibitor targeting a broad set of APOL1-mediated kidney diseases (AMKD), reporting a clinically meaningful reduction in protein levels in urine. Across 12 efficacy-evaluable patients, MZE829 delivered an average 35.6% reduction in proteinuria at week 12, with stronger responses in focal segmental glomerulosclerosis and in subgroups without diabetes. Maze said it will continue enrollment in its Horizon Phase 2 trial and plan discussions with regulators to support a pivotal study. Despite the clinical signal, shares fell sharply on Wednesday, underscoring investor focus on how the results compare with Vertex’s AMKD program and the threshold for translating surrogate endpoints into approval-level evidence.